Targeting galectin-driven regulatory circuits in cancer and fibrosis

Area of Science:

• Glycobiology
• Molecular Biology
• Immunology

Background:

• Galectins are glycan-binding proteins with critical roles in physiological and pathological processes.
• They influence cell fate and function through intracellular and extracellular, glycan-dependent and independent pathways.
• Galectins are implicated in tissue fibrosis and cancer, making them potential therapeutic targets.

Purpose of the Study:

• To review the therapeutic relevance of galectins, specifically galectin 1 (GAL1), GAL3, and GAL9.
• To discuss galectin-targeted strategies for treating fibrotic diseases and cancer.
• To examine the clinical trial outcomes for galectin inhibitors in relevant patient populations.

Main Methods:

• Review of preclinical models of fibrosis and cancer.
• Analysis of various galectin-targeted strategies: small-molecule inhibitors, natural polysaccharides, peptides, peptidomimetics, and biological agents.
• Evaluation of clinical trial data for galectin inhibitors.

Main Results:

• Galectin-targeted strategies demonstrate therapeutic potential in preclinical models.
• Diverse therapeutic approaches, including inhibitors and biological agents, are being investigated.
• Clinical trials are assessing the efficacy of galectin inhibitors in idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis, and cancer.

Conclusions:

• Galectin-targeted therapies hold significant promise for treating fibrotic inflammation and overcoming cancer resistance.
• The rapid advancement in glycobiology research is expected to accelerate the clinical translation of anti-galectin therapeutics.
• Further research and clinical evaluation are crucial for realizing the full therapeutic potential of galectin inhibitors.